These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28796002)

  • 1. Extrahepatic and Intrahepatic Malignancies in Patients With HCV Who Achieve an SVR With Directly Acting Antiviral Agents: Should We be Concerned that DAA Therapy Contributed to this Phenomenon?
    Gaglio PJ
    J Clin Gastroenterol; 2017 Sep; 51(8):657-658. PubMed ID: 28796002
    [No Abstract]   [Full Text] [Related]  

  • 2. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
    PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of hepatitis C virus-specific immunity and sustained virologic response.
    Shrivastava S; Wilson E; Poonia B; Tang L; Osinusi A; Kohli A; Kottilil S
    J Viral Hepat; 2017 Sep; 24(9):742-749. PubMed ID: 28267900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Cacoub P; Desbois AC; Comarmond C; Saadoun D
    Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis.
    Toshikuni N
    Gut Liver; 2017 May; 11(3):335-348. PubMed ID: 27840363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies.
    Ferri C; Feld JJ; Bondin M; Cacoub P
    Antivir Ther; 2018; 23(Suppl 2):23-33. PubMed ID: 30451149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.
    Aziz H; Aziz M; Gill ML
    Viral Immunol; 2018 Apr; 31(3):256-263. PubMed ID: 29664710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
    Jacobson IM; Lim JK; Fried MW
    Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.
    Wilson EM; Rosenthal ES; Kattakuzhy S; Tang L; Kottilil S
    Clin Microbiol Rev; 2017 Jan; 30(1):23-42. PubMed ID: 27795306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antiviral treatment for patients with hepatocellular carcinoma.
    Kushner T; Dieterich D; Saberi B
    Curr Opin Gastroenterol; 2018 May; 34(3):132-139. PubMed ID: 29517502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies.
    Asselah T; Esmat G; Sanai FM; Goulis I; Messinger D; Bakalos G; Waked I
    Adv Ther; 2016 Oct; 33(10):1797-1813. PubMed ID: 27517563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
    Maggi F; Focosi D; Pistello M
    Curr Drug Targets; 2017; 18(7):811-825. PubMed ID: 26245474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.